Highlights nieuwsbrief 4

This newsletter presents you the following key sessions:

1. Video-interview with Jesus Berdeja, MD, PhD, about bb2121 anti-BCMA CAR T cell therapy in patients
    with relapsed / refractory multiple myeloma

2. Quizartinib prolongs overall survival in patients with FLT3-internal tandem duplication–mutated
    relapsed/refractory AML in the phase III QuANTUM-R trial

3. Ravulizumab shows noninferiority versus eculizumab in adult patients with paroxysmal nocturnal
    haemoglobinuria naive to complement inhibitors

4. ELOQUENT-3: Elotuzumab plus pomalidomide/dexamethasone (EPd) shows favorable results over
    Pd for treatment of relapsed/refractory multiple myeloma

5. Better response rates and increased MRD negativity with KRd compared to KCd in newly diagnosed
    multiple myeloma patients, including high-risk patients